Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of TAK-128 in Subjects With Diabetic Peripheral Neuropathy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Has successfully completed protocol 01-04-TL-128-003.~* Female subjects of childbearing potential must be nonpregnant, nonlactating and on an acceptable form of contraception.~* Must be in good health at Enrollment, as determined by a physician at the Month 6 Visit of Protocol 01-04-TL-128-003 (ie, via medical history and physical examination).~* Has clinical laboratory evaluations within the normal reference range for the testing laboratory, unless the results are deemed not clinically significant by the investigator or sponsor, at the Month 6 Visit of Protocol 01-04-TL-128-003.~* Has a creatinine level less than or equal to 2 mg/dL or 176.8 umol/L.~* The subject is willing to follow an American Diabetes Association or similar recommended dietary regimen.~Exclusion Criteria:~* Has developed other neuropathies due to causes other than diabetes such as alcohol abuse liver or renal disease, uremia, toxic exposure, genetic factors, inflammatory demyelinating diseases, monoclonal gammopathies; or endocrine, metabolic or nutritional disorders (included treated or untreated pernicious anemia).~* Has a systolic blood pressure greater than 160 mm HG or diastolic blood pressure is greater than 95 mm HG.~* The subject has an alanine aminotransferase level of greater than 1.5 times the upper limit of normal, active liver disease, or jaundice.~* Has a significant, actively treated or unstable pulmonary, cardiovascular, gastrointestinal, hepatic, hematologic, musculoskeletal, or endocrine (other than diabetes mellitus or stably treated hypothyroidism) disease.~* Cannot use any of the following prescription medications throughout the duration of the study, including:~  * Lipoic acid.~ * Linolenic acid (primrose oil).~ * Inositol.~ * Topiramate.~ * Acetyl-L-Carnitine.~ * Nerve growth factors.~ * Capsaicin.~* Has any other serious disease or condition at the Month 6 Visit of Protocol 01-04-TL-128-003 or at the Baseline/Rollover Visit that might affect life expectancy or make it difficult to successfully manage and follow the subject according to the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- TAK-128 100 mg QD (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).